Navigation Links
VEGF Trap-Eye Phase 2 Wet AMD Results Reported at ARVO Annual,Meeting

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--May 9, 2007 - Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced positive results from several studies evaluating the VEGF Trap-Eye in the neovascular form of age-related macular degeneration (wet AMD) and diabetic macular edema (DME). These findings were presented this week at the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO). The data reported at the meeting from a pre-planned interim analysis of a Phase 2 randomized study of the VEGF Trap-Eye in patients with wet AMD and a Phase 1 DME trial are available on the Regeneron website (www.regeneron.com on the Events page, under the Investor Relations heading).

"We are very encouraged by the preliminary observation in the Phase 2 wet AMD trial that the most intense dosing regimen studied, 2 milligrams delivered by intravitreal injection every 4 weeks, resulted in an average gain of more than 10 letters after 12 weeks of treatment," said George D. Yancopoulos, M.D., Ph.D., President of Regeneron Research Laboratories. "Perhaps equally important is that after receiving only a single dose of the VEGF Trap-Eye, patients on average had an improvement in the number of letters read both 8 and 12 weeks after treatment. Although significantly more clinical testing is required, the VEGF Trap-Eye may offer the potential to improve vision in patients with wet AMD with a regular dosing regimen that is less frequent than monthly."

Regeneron and Bayer HealthCare AG plan to initiate the VEGF Trap-Eye Phase 3 program in wet AMD in the third quarter of 2007. In the first Phase 3 trial, the companies currently plan to evaluate the VEGF Trap-Eye using 4 and 8 week dosing intervals in direct comparison with ranibizumab (Lucentis(R), a registered trademark of Genentech, Inc.) administered every 4 weeks according to its label. The companies are collaborating on the global development of the VE
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Positive Interim Phase 2 Data Reported for VEGF Trap-Eye in Age-Related Macular Degeneration
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: VEGF Trap Eye Phase Wet AMD Results Reported ARVO Annual Meeting
(Date:12/15/2014)... Research and Markets ( http://www.researchandmarkets.com/research/32cmct/inferior_vena ) ... Cava (IVC) Filters - Global Trends, Estimates and Forecasts, ... http://photos.prnewswire.com/prnh/20130307/600769 Global Inferior Vena ... million by 2016. The North America ... value while Europe claims approximately ...
(Date:12/15/2014)... Norway , December 15, 2014 ... innovative drugs for aggressive drug resistant cancers, today announces ... in a private placing from new and existing investors. ... financing to support the development of its pipeline of ... program for its lead drug candidate, BGB324, a first-in-class ...
(Date:12/15/2014)... Dec. 15, 2014  Inovio Pharmaceuticals, Inc. (NASDAQ: ... been added to the NASDAQ Biotechnology Index (NBI). ... become effective upon market open on December 22, ... designed to track the performance of a set ... biotechnology or pharmaceutical according to the Industry Classification ...
Breaking Medicine Technology:Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 2Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 4BerGenBio Completes NOK90 Million Fundraising 2Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 2Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 3Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 4
... new understanding of,the role played by the protein ... novel therapies to rebuild muscle tissue,damaged by disease, ... Institute for Cancer Research and Molecular Medicine at ... The researchers reported their findings, "Cdk9-55: A ...
... implantable,medical device, developed in collaboration with Mayo Clinic ... alternative to existing,bariatric surgeries, according to findings published ... In a six-month open label trial involving three ... obese participants who received the,vagal nerve blocking device, ...
Cached Medicine Technology:International Team Locates Key Player in Muscle Regeneration 2Device Blocking Stomach Nerve Signals Shows Promise in Obesity 2Device Blocking Stomach Nerve Signals Shows Promise in Obesity 3
(Date:12/17/2014)... Dr. Myo Nwe is the co-author of ... the Future” and co-founder of the Ace Medical Weight Loss ... takes a broad look at the industry of weight loss, ... scrutiny. On film and in television shows, however, she says ... social aspects and played for basic laughs, which she believes ...
(Date:12/17/2014)... 2014 In its comprehensive analysis of ... Argus Claim Review division have recently identified out-of-network and ... ways savings are achieved on behalf of employer-clients. ... dollars in savings to Argus each year, with a ... explained by Tom Doney, Cypress president and CEO, these ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... one worrisome phenomenon is when an illness that originated in ... as zoonosis -- is not uncommon and keeps researchers on ... disease might make inroads into the human population. A ... the culprits in this case were guinea pigs. More specifically, ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. ... to improve overall health, but a growing body of evidence ... new review finds. In fact, the benefits were similar ... lead researcher Paula Chu, a doctoral candidate at Harvard University,s ... clinical trials, found that people randomly assigned to take yoga ...
(Date:12/15/2014)... (PRWEB) December 15, 2014 Main Street ... clinic, is weighing in on a new study providing ... on the oral hygiene of children. , Sufficient enough ... drinks, such as pop or juice drinks, with the ... looming, however, is whether drinks listed as 100% fruit ...
Breaking Medicine News(10 mins):Health News:Obesity Should Not Be a Hollywood Punchline, Weight Loss Doc Says 2Health News:Out-of-Network & Medical Necessity Reviews among Top Ways TPA Identifies Significant Medical Claim Savings 2Health News:Guinea Pigs Can Be Source of Serious Strep Infection 2Health News:Guinea Pigs Can Be Source of Serious Strep Infection 3Health News:Yoga May Cut Heart Disease Risk Factors 2Health News:Yoga May Cut Heart Disease Risk Factors 3Health News:Main Street Dental Team, Unionville’s Most Innovative Dental Clinic, Comments on New Study Relating Pure Fruit Juice to Poor Oral Hygiene 2
... offers a significantly higher survival rate than either external-beam radiation ... researchers at UCSF. The differences among therapies were more ... researchers say, that in many cases surgery should play a ... that is likely to recur or spread. ...
... Reinberg HealthDay Reporter , THURSDAY, Aug. 5 (HealthDay ... having a miscarriage stand the best chance of having a ... The time that couples should wait after a miscarriage ... among medical experts. Some doctors say there is no reason ...
... HealthDay Reporter , THURSDAY, Aug. 5 (HealthDay News) ... a lowered risk of heart disease and diabetes, being ... of glaucoma, Harvard researchers say. This new finding ... of developing primary open-angle glaucoma (POAG), one of the ...
... Researchers looking for differences in eating habits of African ... diabetes uncovered an unexpected result: No matter what the blood ... same. African Americans are 1.8 times more likely to ... be obese than are non-Hispanic whites, according to federal health ...
... published today in the scientific journal Addiction ... the manufacture of methamphetamine have caused a drop in ... In 2005 Mexico began controlling its ... manufacture of methamphetamine), and in 2008 it became the ...
... hard to find, here,s good news for the under-qualified: ... ( http://www.fasebj.org ) shows that being a highly ... taking on leading management positions at research institutions. This ... may exist at research institutions where top-cited scientists either ...
Cached Medicine News:Health News:Surgery better than radiation, hormone treatments for some prostate cancer, study shows 2Health News:Surgery better than radiation, hormone treatments for some prostate cancer, study shows 3Health News:Women Can Safely Get Pregnant Right After Miscarriage, Study Shows 2Health News:Women Can Safely Get Pregnant Right After Miscarriage, Study Shows 3Health News:Excess Weight May Protect Women From Type of Glaucoma 2Health News:Excess Weight May Protect Women From Type of Glaucoma 3Health News:Diabetes or not, dietary habits of Aftrican-Americans are similar 2Health News:Diabetes or not, dietary habits of Aftrican-Americans are similar 3Health News:Diabetes or not, dietary habits of Aftrican-Americans are similar 4Health News:Help wanted: Highly cited researchers needed for high-ranking positions at research institutions 2
... in the field of Urodynamics, Albyn Medical recognised ... new chair is manufactured from the highest quality ... can be improved considerably if the patient is ... this aspect was given a high priority in ...
The Triage Drugs of Abuse Panel is the leading rapid drug screen used by U.S. hospitals. The Triage Drugs of Abuse Panel is a small, handheld urine test that provides qualitative results for up to n...
... The Advanced Model 3900 Multi-Sample ... for laboratories processing moderate to high ... industry-preferred method of freezing-point technology for ... combined with high, continuous throughput, the ...
... The Advanced® 2020 Multi-Sample Osmometer provides ... industrial, and research settings. These results ... freezing-point method, which determines total concentration. ... on-board data management, automated sample handling, ...
Medicine Products: